Transforming the treatment of aortic regurgitation
JenaValve is redefining what it means to treat patients with severe aortic regurgitation.
Update from TCT 2024: 2-year Data
Watch Video
Innovations in TAVR:
The JenaValve Trilogy System
Learn More
About Us
JenaValve is a global medical device company
dedicated to supporting physicians
addresses the needs of patients with structural heart disease.
Get in touch today to learn more about JenaValve and the Trilogy System
*Indications: The JenaValve Trilogy Heart Valve System is indicated for use in patients with native symptomatic, severe aortic regurgitation (AR) or symptomatic, severe aortic stenosis (AS), who are judged by a Heart Team (including a cardiac surgeon), to be at high or greater risk for surgical aortic valve replacement (AVR), with an STS score ≥ 8% at 30 days, or other comorbidities (e.g., porcelain aorta, frailty, chest wall irradiation) that are not captured by the STS risk calculator.
Contraindications: The JenaValve Trilogy Heart Valve System is contraindicated for use in patients who have known hypersensitivity or contraindication to Nitinol (titanium and/or nickel), an anti-coagulation/anti-platelet regimen or contrast medium that cannot be managed with premedication, or who have active bacterial endocarditis or other active infections.
US: CAUTION – Investigational Device. Limited by Federal (or United States) law to investigational use.